HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis.

AbstractBACKGROUND & AIMS:
Cirrhotic patients with recurrent ascites frequently require paracentesis despite diuretic therapy. Vasopressin receptor antagonists, by increasing free water clearance, may reduce the recurrence of ascites. To investigate the effects of the addition of a vasopressin V(2) receptor antagonist, satavaptan, to 100mg spironolactone on ascites recurrence after a large volume paracentesis in patients with liver cirrhosis irrespective of the presence of hyponatraemia.
METHODS:
One hundred and fifty one cirrhotic patients with recurrent ascites with or without hyponatraemia, and normal to mildly abnormal renal function were randomised in a double-blind study to receive either 5mg (n=39), 12.5mg (n=36), 25mg (n=40) of satavaptan or placebo (n=36) for 12 weeks. Their Child-Pugh scores were 9.2+/-1.3, 8.7+/-1.7, 8.8+/-1.3, and 9.0+/-1.5, respectively.
RESULTS:
Median time to first paracentesis was 23, 26, and 17 days with satavaptan 5, 12.5, and 25mg, respectively, versus 14 days with placebo (ns for all doses). The frequency of paracenteses was decreased significantly (p<0.05) in all satavaptan groups versus placebo. Mean increase in ascites was 2.82+/-0.48 L/week for placebo versus 2.12+/-0.40, 2.14+/-0.33, and 2.06+/-0.40 L/week for the 5, 12.5, and 25mg of satavaptan, respectively (ns for all doses). Similar numbers of patients experienced major adverse events in all groups. Increases in serum creatinine, orthostatic changes in systolic pressure and thirst were more common with satavaptan.
CONCLUSIONS:
Satavaptan has the potential to reduce recurrence of ascites after a large volume paracentesis at doses from 5 to 25mg in cirrhotic patients with ascites.
AuthorsFlorence Wong, Pere Gines, Hugh Watson, Yves Horsmans, Paolo Angeli, Paul Gow, Pascal Minini, Mauro Bernardi
JournalJournal of hepatology (J Hepatol) Vol. 53 Issue 2 Pg. 283-90 (Aug 2010) ISSN: 1600-0641 [Electronic] England
PMID20541828 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
CopyrightCopyright 2010 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Antidiuretic Hormone Receptor Antagonists
  • Diuretics
  • Morpholines
  • Spiro Compounds
  • Spironolactone
  • satavaptan
  • Creatinine
Topics
  • Aged
  • Antidiuretic Hormone Receptor Antagonists
  • Ascites (etiology, prevention & control, therapy)
  • Combined Modality Therapy
  • Creatinine (blood)
  • Diuretics (therapeutic use)
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Drug Therapy, Combination
  • Female
  • Humans
  • Hyponatremia (drug therapy, metabolism)
  • Liver Cirrhosis (complications)
  • Male
  • Middle Aged
  • Morpholines (adverse effects, therapeutic use)
  • Paracentesis
  • Secondary Prevention
  • Spiro Compounds (adverse effects, therapeutic use)
  • Spironolactone (therapeutic use)
  • Thirst
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: